You're describing a molecule with a long and rather complex chemical name! Let's break it down and understand its importance:
**1-butyl-N-[(4-chlorophenyl)methyl]-4-hydroxy-2-oxo-3-quinolinecarboxamide**
This name tells us about the structure of the molecule:
* **Quinolinecarboxamide:** The core structure is a quinoline ring, a nitrogen-containing aromatic ring system, with a carboxamide group attached to it.
* **4-hydroxy:** A hydroxyl group (OH) is attached to the 4th position on the quinoline ring.
* **2-oxo:** A ketone group (C=O) is attached to the 2nd position on the quinoline ring.
* **1-butyl:** A butyl group (four carbon chain) is attached to the 1st position on the quinoline ring.
* **N-[(4-chlorophenyl)methyl]:** This part describes a substituent attached to the nitrogen atom of the carboxamide group. It consists of a benzyl group (methylene linked to a benzene ring) with a chlorine atom attached at the 4th position on the benzene ring.
**Why is it important for research?**
The specific molecule you described doesn't have a well-established research history or a common name, so I can't give you details on its specific importance. However, molecules with similar structures are often investigated for their potential pharmacological activity. Here's why:
* **Quinoline derivatives:** Quinoline-based compounds have a rich history in medicinal chemistry. They have shown activity in various therapeutic areas, including:
* **Antimicrobial activity:** Some quinoline derivatives have antibacterial, antifungal, and antiparasitic properties.
* **Anti-inflammatory activity:** These compounds can inhibit inflammation and have potential for treating inflammatory diseases.
* **Anticancer activity:** Some quinolines have shown promise as potential cancer chemotherapeutic agents.
* **Anti-malarial activity:** Quinine, a natural quinoline alkaloid, has been a mainstay in malaria treatment for centuries.
* **Carboxamide group:** The carboxamide group often contributes to a compound's ability to bind to biological targets, which is essential for drug action.
* **Substituents:** The presence of specific substituents like the hydroxyl group and the chloro-substituted benzyl group can influence the molecule's properties, potentially enhancing its activity or altering its target selectivity.
**To find out more about the specific molecule you mentioned:**
* **Chemical databases:** Search for the full chemical name in databases like PubChem or ChemSpider. These databases might provide information on its potential biological activity, synthesis methods, and any relevant research papers.
* **Scientific literature:** Use the full chemical name or a related structure to search in scientific databases like PubMed or Google Scholar. This will help you find research articles that have investigated similar molecules.
Remember, without specific research context, it's difficult to pinpoint the exact significance of this particular molecule. However, its structure points to potential applications in drug discovery and research.
ID Source | ID |
---|---|
PubMed CID | 54679562 |
CHEMBL ID | 1460151 |
CHEBI ID | 107570 |
Synonym |
---|
OPREA1_489718 |
OPREA1_862988 |
MLS001202795 |
1-butyl-4-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid 4-chloro-benzylamide |
smr000513679 |
CHEBI:107570 |
AKOS000622404 |
HMS2818F06 |
CHEMBL1460151 |
1-butyl-n-[(4-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide |
1-butyl-n-[(4-chlorophenyl)methyl]-4-hydroxy-2-oxo-3-quinolinecarboxamide |
Q27185895 |
sr-01000588911 |
SR-01000588911-1 |
1-bu-4-ho-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid 4-chloro-benzylamide |
BRD-K13162652-001-09-0 |
Class | Description |
---|---|
aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.6684 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 3.9811 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
PINK1 | Homo sapiens (human) | Potency | 44.6684 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
67.9K protein | Vaccinia virus | Potency | 2.2387 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
Parkin | Homo sapiens (human) | Potency | 44.6684 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 15.8489 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
P53 | Homo sapiens (human) | Potency | 70.7946 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
geminin | Homo sapiens (human) | Potency | 16.4687 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 44.6684 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |